Skip to content

The Application of MRD in the Management of Upper Tract Urothelial Carcinoma

The Application of MRD in the Management of Upper Tract Urothelial Carcinoma

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300078939
Enrollment
Unknown
Registered
2023-12-21
Start date
2023-12-31
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upper Tract Urothelial Carcinoma

Interventions

Sponsors

The Second Hospital of Dalian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1.Clinical diagnosis of surgically resectable primary upper tract urothelial carcinoma (UTUC); 2.Able to provide written informed consent, comprehend, and agree to comply with study requirements; 3.Males or females aged over 18 years; 4.Treatment-naive patients who have not previously undergone any therapy and agree to receive treatment; 5.Underwent CT examination within 1 month prior, showing no evidence of significant metastasis; 6.Patients must be able to provide fresh tumor tissue (tumor tissue specimen 50mg/needle, using 18G needles for 2 punctures) along with its pathological report; 7.ECOG performance status of =1; 8.Patients must have at least one measurable lesion (evaluated according to RECIST v1.1); 9.Patients must have adequate organ function, with laboratory test values within normal ranges or meeting specified criteria within 7 days before treatment.

Exclusion criteria

Exclusion criteria: 1.Patients with a history of other malignant tumors within the last 5 years, except for basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer, who have received potentially curative treatment and have not experienced a relapse within 5 years before the start of treatment, are eligible for the study. 2.Subjects who have received any approved antitumor therapy before starting the study treatment. 3.Severe chronic or active infections requiring systemic antibacterial, antifungal, or antiviral treatment, including pulmonary tuberculosis infection, etc. 4.Known human immunodeficiency virus infection. 5.Prior allogeneic stem cell transplantation or organ transplantation. 6.The investigator judges that the patient's compliance during the study period is inadequate.

Design outcomes

Primary

MeasureTime frame
DFS;

Countries

China

Contacts

Public ContactWang Liang

The Second Hospital of Dalian Medical University

wangldoct@sina.com+86 177 0987 1907

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026